Scientists hope that a “cannabis genome” could mean better results for growers and patients – but will it allow big pharma to take over?
The August announcement that Massachusetts-based company Medicinal Genomics had sequenced the entire genome of Cannabis sativaL. received much national attention. While the development makes for attention-grabbing headlines—“Marijuana Genome Sequenced for Health, Not Highs,” “Science Cracks the Cannabis Genome”—how will it actually impact research and public health?
Medicinal Genomics founder Kevin McKernan became interested in decoding the cannabis genome when working with a clinical oncologist to sequence the DNA of cancer tumors and patients.